SCHEMBL7876448

SCHEMBL7876448

COC(=O)CC(NC(=O)c1ccccc1)c1ccc(OC)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.58
NPSR1 Q6W5P4 2/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
ROCK2 O75116 1/20 0.53
ROCK1 Q13464 1/20 0.53
TNF P01375 2/20 0.53
PDE4A P27815 1/20 0.53
PDE4B Q07343 1/20 0.53
PDE4C Q08493 1/20 0.53
PDE4D Q08499 1/20 0.53
HPGD P15428 1/20 0.51
ITGB3 P05106 1/20 0.51
ITGA2B P08514 1/20 0.51
ITGA2 P17301 1/20 0.51
TAS1R3 Q7RTX0 2/20 0.50
TAS1R1 Q7RTX1 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7876188 0.90 POLB (0.58) POLBNPSR1LMNAMAPTKMT2A
SCHEMBL7872607 0.89 TAS1R3 (0.53) POLBNPSR1LMNAMAPTKMT2A
SCHEMBL7876199 0.88 HPGD (0.52) POLBNPSR1LMNAMAPTKMT2A
SCHEMBL7867559 0.87 ITGB3 (0.49) POLBNPSR1LMNAMAPTKMT2A
SCHEMBL7867590 0.87 NPSR1 (0.71) POLBNPSR1LMNAMAPTKMT2A
SCHEMBL8174992 0.86 MAPK1 (0.54) POLBNPSR1LMNAMAPTKMT2A
SCHEMBL7872598 0.84 TNF (0.55) NPSR1LMNAMAPTKMT2AMEN1
SCHEMBL14198862 0.84 MEN1 (0.63) POLBLMNAMAPTKMT2AMEN1
SCHEMBL12226572 0.84 MEN1 (0.63) POLBLMNAMAPTKMT2AMEN1
SCHEMBL27781112 0.84 MEN1 (0.63) POLBLMNAMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0800505-B1 NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES CELGENE CORP (US) 2001-09-26 EP disclosed
US-6284780-B1 PREVENT TUMOR NECROSIS FACTOR RETROVIRUS REPRODUCTION CELGENE CORPORATION 2001-09-04 US disclosed
US-6046221-A USEFUL FOR REDUCING LEVELS OF TUMOR NECROSIS FACTOR-ALPHA IN A MAMMAL CELGENE CORPORATION (US) 2000-04-04 US disclosed
US-5801195-A TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION CELGENE CORPORATION (US) 1998-09-01 US disclosed
US-5736570-A ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS CELGENE CORPORATION (US) 1998-04-07 US disclosed
EP-0800505-A1 NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES CELGENE CORPORATION (US) 1997-10-15 EP disclosed
WO-1996020915-A1 NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES CELGENE CORPORATION (US) 1996-07-11 WO disclosed